Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tasigna
Nilotinib is a tyrosine kinase inhibitor (TKI) primarily used to treat chronic myeloid leukemia (CML). It works by blocking specific proteins that promote the growth of cancer cells, thereby slowing or stopping the progression of the disease. It's often prescribed after imatinib resistance or intolerance.
For treating chronic myeloid leukemia (CML) in chronic and accelerated phases in adults resistant to or intolerant of prior therapy including imatinib.
Severe hepatotoxicity, including fatalities, has been reported; monitor liver function and discontinue NILOTINIB if hepatotoxicity is suspected. QT prolongation and sudden death have been reported; correct electrolyte abnormalities before initiating treatment. NILOTINIB may cause severe myelosuppression; monitor blood counts frequently.
Outcome:
Increased nilotinib plasma concentration
Mechanism:
Inhibition of CYP3A4-mediated metabolism
Outcome:
Increased midazolam plasma concentration
Mechanism:
Inhibition of CYP3A4-mediated metabolism
Outcome:
No clinically significant interaction expected
Mechanism:
Not applicable
Most likely new formulation: A combination therapy with other targeted agents (Year: 2026, 60% confidence)
Based on ongoing clinical trials and expanding indications, there is a 70% likelihood of nilotinib's use expanding to other related cancers in the next 5 years.
Antineoplastic Agent, Tyrosine Kinase Inhibitor
4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide